Anterior gradient protein

From Proteopedia

Revision as of 01:35, 10 January 2021 by Marion Ottinger (Talk | contribs)

(diff) ←Older revision | Current revision (diff) | Newer revision→ (diff)

Anterior Gradient Protein 2

AGR2_HUMAN

Originally discovered in Xenopus laevis as a cement gland differentiation regulator ^[1], (AGR2) in humans is a protein chaperone involved in proteostasis, mainly for proteins expressed in epithelial cells, such as in the esophagus or lungs^[2]. AGR2, composed of 175 amino acids, belongs to the protein disulfide isomerase family (PDI).

Structural highlights

This protein contains various remarkable domains which can be visualized in the figure.

 - an unfolded NH2 terminal sequence with a peptide signal from the first to the 21st amino acid.

 - an active pseudo-thioredoxin domain (CXXS) from the .

Called “pseudo” because there is only one active cysteine residue ()

 - a terminal COOH sequence with a KTEL motif from the

Moreover, this protein can be found as a monomer or a dimer, thanks to a specific motif which is EALYK between the . There are intermolecular salt bridges involving E60 and K64, in order to fix the second monomer. The CXXS domain is on the opposite side to avoid any disulfide exchange. Nevertheless, the dimeric structure is oxidation-dependent which means that C81 is necessary.

Functions

AGR2 does not have the same roles if it is found in the extracellular matrix, or the intracellular milieu. According to the patterns found in N-ter and C-ter it seems obvious that AGR2 is a protein intended to reside in the ER, so inside the cells. Indeed, N-ter sequence directs the import of AGR2 into the ER and is responsible for the cell adhesion properties of AGR2, and the C-ter sequence prevents the AGR2 from being exported out of the ER. Within the latter, AGR2 allows the folding of nascent proteins in the ER, in order to mature them, through its CXXS domain, which catalyzes the formation and isomerization of disulfide bonds during protein folding. This protein mainly allows the folding of cysteine-rich proteins, such as the protein coded by the gene MUC2, by forming disulfide bridges. However, it happens that AGR2 is found outside the ER despite its function as a disulfide isomerase and its C-ter sequence, the reason remains unclear. In a cancerous medium such as serum or urine, extracellular AGR2 is often found in large quantities.

Disease

Different links between this protein and the appearance of some pathologies have been highlighted. Specially concerning diseases such as cancers or inflammatory diseases. In fact, as AGR2 proteins are involved in many biological pathways such as proteostasis or cell signaling for example, it has been possible to deduce that its involvement in proteostasis may play an important role in the development of tumors and more specifically in the multiplication of abnormal or mutated proteins in tumor cells. This protein plays a role in hormone-dependent cancers such as breast and prostate cancer. Indeed, AGR2 is not constitutive and its expression is regulated by signals. In this regard, it has been proven that when ARG2 expression is detected in women with breast cancer, their prognosis is poor. Furthermore, in a study on inflammatory diseases, it was found that a mutation on () in AGR2 causes an alteration in the interactions with mucin proteins (transmembrane protein, component of the mucus covering certain epithelial cells). In this pathway, the overexpression of AGR2 can cause an overexpression of mucus which, in breast cancer, participates in the proliferation of cancer cells and metastasis. The AGR2 protein can form complexes with Reptin which is recognized as an anti-oncogene. However, it binds more easily when the protein is in dimeric form. Thus, a mutation on () site, giving the protein a monomeric form, would reduce cancer repression by Reptin. Finally, it has also been studied that the expression of AGR2 in breast cancer patients confers chemoresistance to cancer cell growth inhibitors such as Tamoxifen. However, the mechanism involved is not very clear yet.

References

↑ Delom F, Mohtar MA, Hupp T, Fessart D. The anterior gradient-2 interactome. Am J Physiol Cell Physiol. 2020 Jan 1;318(1):C40-C47. doi:, 10.1152/ajpcell.00532.2018. Epub 2019 Oct 23. PMID:31644305 doi:http://dx.doi.org/10.1152/ajpcell.00532.2018
↑ Moidu NA, A Rahman NS, Syafruddin SE, Low TY, Mohtar MA. Secretion of pro-oncogenic AGR2 protein in cancer. Heliyon. 2020 Sep 23;6(9):e05000. doi: 10.1016/j.heliyon.2020.e05000. eCollection, 2020 Sep. PMID:33005802 doi:http://dx.doi.org/10.1016/j.heliyon.2020.e05000

Proteopedia Page Contributors and Editors (what is this?)

Loane Schertzer, Michal Harel, Marion Ottinger, Léa Moyon, Jaime Prilusky

Retrieved from "http://52.214.119.220/wiki/index.php/Anterior_gradient_protein"

Anterior gradient protein

From Proteopedia